We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Mingyuan Medicare Announces Collaboration with CHGC and SBC
News

Mingyuan Medicare Announces Collaboration with CHGC and SBC

Mingyuan Medicare Announces Collaboration with CHGC and SBC
News

Mingyuan Medicare Announces Collaboration with CHGC and SBC

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Mingyuan Medicare Announces Collaboration with CHGC and SBC"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Board of Mingyuan Medicare Development Company Limited announces that the Company had entered into a milestone co-operation agreement (the "Co-operation Agreement") with Chinese National Human Genome Centre in Shanghai (CHGC) and Shanghai Biochip Company Limited (SBC) on the joint establishment of a dynamic technology platform with rapid response capability to develop diagnostic kits for early detection of major or new infectious diseases on demand basis.

The two products above are able to qualitatively detect new Influenza A/H1N1 virus, seasonal Influenza A H1 virus and Non-A H1 Influenza virus and identify with fluorescent labels, being applicable to respiratory tract sample test (nasopharynx swab / aspirate or nasal cavity wash / aspirate).

The diagnostic kits are able to detect Influenza A viruses at a very early stage of infection. As the test result is available in 2 hours, the kits can be used in hospitals, border checkpoints and clinics to help diagnose suspected symptomatic and asymptomatic infections and thus effectively prevent the virus from further spreading.

Mr. Henry Chien, CEO of Mingyuan Medicare, said, "We are honoured to be a partner of CHGC and SBC. The technology platform with rapid response capability to develop diagnostic kits for early detection of major or new infectious diseases is believed to play an important role in the development of human health. Currently, Influenza A viruses (including the recent outbreak of Influenza A (H1N1) virus) is a highly infectious disease which has long been regarded as a major health hazard to human. Furthermore, the World Health Organization may soon raise the influenza pandemic alert level from Phase 5 to Phase 6, the highest pandemic phase. The two newly-developed advanced diagnostic kits for detecting Influenza A viruses help to identify Human Swine Flu (A H1N1) patients, and this is believed to be critical to effectively preventing the spread of the infectious disease and to improve the chance of recovery."
Advertisement